Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + pomalidomide + dexamethasone (KPd) ± daratumumab in relapsed/refractory multiple myeloma (real-world observational study)
ChiCTR2500097217Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib, pomalidomide, dexamethasone and daratumumab in multiple myeloma (MM), sponsored by Peking Union Medical College Hospital. Primary endpoint: Overall response rate (ORR). Started Feb 2025; status: recruiting.
02
Drugs
carfilzomibpomalidomidedexamethasonedaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500097217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097217.